Physician-authored. Peer-reviewed sources. No sponsored content. Just research you can trust.
Deep-dive into the science behind peptides and protocols.
Oral NMN, oral NR, and direct NAD+ infusion produce strikingly different tissue distributions. Understanding the Slc12a8 transporter and first-pass metabolism explains why route of administration — not just dose — determines which organs actually see an NAD+ rise.
The route of administration — oral NMN, oral NR, or parenteral NAD+ — dramatically changes which tissues actually receive NAD+ precursor uplift. Pharmacokinetics, not dose, often determines clinical outcome.
AMPK is the master energy-sensing kinase that switches cells from anabolic storage to catabolic fat oxidation. Research links its activation to improved insulin sensitivity, autophagy, and healthspan.
SNAP-8 is a topical octapeptide that competitively inhibits the SNARE complex — the same molecular machinery blocked by botulinum toxin — offering a non-injectable approach to expression line attenuation.
SNAP-8 is an eight-amino-acid peptide modeled on the N-terminus of SNAP-25 that competitively interferes with SNARE complex assembly — offering a topical mechanism for softening expression lines distinct from botulinum toxin injection.
Delta sleep-inducing peptide (DSIP) is a nine-amino-acid neuropeptide that influences slow-wave sleep through GABAergic modulation and HPA-axis suppression — a mechanism profile distinct from benzodiazepines or melatonin.
Semax is a synthetic heptapeptide derived from ACTH(4-10) that dramatically upregulates BDNF expression in the hippocampus while modulating dopamine and serotonin systems — making it one of the most studied neuroprotective peptides in Russian clinical literature.
Semax is a synthetic ACTH(4-10) fragment developed in Russia that rapidly upregulates BDNF and modulates monoaminergic systems — a mechanism distinct from stimulants or racetams.
Tirzepatide is the first dual GIP/GLP-1 receptor agonist approved by the FDA, producing weight loss and glycemic improvements that exceed every prior incretin therapy in head-to-head trials.
PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder. Learn about its unique central nervous system mechanism.